论文部分内容阅读
目的观察尤瑞克林治疗急性脑梗死的临床疗效。方法将200例急性脑梗死患者随机分为观察组和对照组各100例。观察组采用尤瑞克林联合依达拉奉进行治疗,对照组单纯使用依达拉奉进行治疗,治疗14d后观察治疗效果。结果治疗观察组患者总有效率为89%显著大于对照组的66%,差异有统计学意义(P<0.05)。结论尤瑞克林联合依达拉奉治疗急性脑梗死临床疗效确切,不良反应少,长期安全有效,值得在临床中进行推广和应用。
Objective To observe the clinical efficacy of urelin in the treatment of acute cerebral infarction. Methods 200 cases of acute cerebral infarction were randomly divided into observation group and control group of 100 cases. The observation group was treated with uracil combined with edaravone. The control group was treated with edaravone only. The therapeutic effect was observed after 14 days of treatment. Results The total effective rate of the treatment observation group was 89%, which was significantly higher than that of the control group (66%), the difference was statistically significant (P <0.05). Conclusion The combination of erilachlor and edaravone in the treatment of acute cerebral infarction has definite clinical curative effect, few adverse reactions, long-term safety and effectiveness, which is worth to be popularized and applied in clinic.